-
1
-
-
36949061541
-
Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor
-
Goldin A, Venditti JM, Kline I, Mantel N. Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 1966;212:1548-50.
-
(1966)
Nature
, vol.212
, pp. 1548-1550
-
-
Goldin, A.1
Venditti, J.M.2
Kline, I.3
Mantel, N.4
-
2
-
-
0014608878
-
Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates
-
Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 1969;48:2140-55.
-
(1969)
J Clin Invest
, vol.48
, pp. 2140-2155
-
-
Hryniuk, W.M.1
Bertino, J.R.2
-
3
-
-
0010348233
-
Long-term remissions in childhood acute leukemia: Use of infrequent infusions of methotrexate; supportive roles of platelet transfusions and citrovorum factor
-
Phila
-
Djerassi I, Abir E, Royer GL, Treat CL. Long-term remissions in childhood acute leukemia: use of infrequent infusions of methotrexate; supportive roles of platelet transfusions and citrovorum factor. Clin Pediatr (Phila) 1966;5:502-9.
-
(1966)
Clin Pediatr
, vol.5
, pp. 502-509
-
-
Djerassi, I.1
Abir, E.2
Royer, G.L.3
Treat, C.L.4
-
4
-
-
0016242550
-
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma
-
Jaffe N, Frei E III, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:994-7.
-
(1974)
N Engl J Med
, vol.291
, pp. 994-997
-
-
Jaffe, N.1
Frei III, E.2
Traggis, D.3
Bishop, Y.4
-
5
-
-
0017890469
-
"Single"-agent activity of high-dose methotrexate with citrovorum factor rescue
-
Von Hoff DD, Rozencweig M, Louie AC, Bender RA, Muggia FM. "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 1978;62:233-5.
-
(1978)
Cancer Treat Rep
, vol.62
, pp. 233-235
-
-
Von Hoff, D.D.1
Rozencweig, M.2
Louie, A.C.3
Bender, R.A.4
Muggia, F.M.5
-
6
-
-
33846693322
-
The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals
-
DOI 10.1097/MOG.0b013e32801b3c8f, PII 0000157420070300000011
-
Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007;23:164-70. (Pubitemid 46192971)
-
(2007)
Current Opinion in Gastroenterology
, vol.23
, Issue.2
, pp. 164-170
-
-
Revollo, J.R.1
Grimm, A.A.2
Imai, S.-I.3
-
7
-
-
10944270187
-
The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells
-
DOI 10.1074/jbc.M408388200
-
Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004;279:50754-63. (Pubitemid 40017813)
-
(2004)
Journal of Biological Chemistry
, vol.279
, Issue.49
, pp. 50754-50763
-
-
Revollo, J.R.1
Grimm, A.A.2
Imai, S.-I.3
-
8
-
-
62649156291
-
Nampt: Linking NAD biology, metabolism and cancer
-
Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009;20:130-8.
-
(2009)
Trends Endocrinol Metab
, vol.20
, pp. 130-138
-
-
Garten, A.1
Petzold, S.2
Korner, A.3
Imai, S.4
Kiess, W.5
-
9
-
-
0242526050
-
FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis
-
Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42. (Pubitemid 37413486)
-
(2003)
Cancer Research
, vol.63
, Issue.21
, pp. 7436-7442
-
-
Hasmann, M.1
Schemainda, I.2
-
11
-
-
0034482908
-
Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro
-
Hansen CM, Hansen D, Holm PK, Larsson R, Binderup L. Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. Anticancer Res 2000;20:4211-20. (Pubitemid 32143725)
-
(2000)
Anticancer Research
, vol.20
, Issue.6 B
, pp. 4211-4220
-
-
Hansen, C.M.1
Hansen, D.2
Holm, P.K.3
Larsson, R.4
Binderup, L.5
-
12
-
-
0037091007
-
Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells
-
DOI 10.1016/S0006-2952(02)00890-0, PII S0006295202008900
-
Lovborg H, Martinsson P, Gullbo J, Ekelund S, Nygren P, Larsson R. Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochem Pharmacol 2002;63:1491-8. (Pubitemid 34457965)
-
(2002)
Biochemical Pharmacology
, vol.63
, Issue.8
, pp. 1491-1498
-
-
Lovborg, H.1
Martinsson, P.2
Gullbo, J.3
Ekelund, S.4
Nygren, P.5
Larsson, R.6
-
13
-
-
64049094455
-
Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo
-
Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 2009;77:1612-20.
-
(2009)
Biochem Pharmacol
, vol.77
, pp. 1612-1620
-
-
Formentini, L.1
Moroni, F.2
Chiarugi, A.3
-
16
-
-
38149105811
-
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
-
Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008;26:45-51.
-
(2008)
Invest New Drugs
, vol.26
, pp. 45-51
-
-
Holen, K.1
Saltz, L.B.2
Hollywood, E.3
Burk, K.4
Hanauske, A.R.5
-
17
-
-
14844291424
-
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study
-
DOI 10.1016/j.ejca.2004.12.023
-
Ravaud A, Cerny T, Terret C, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41:702-7. (Pubitemid 40342552)
-
(2005)
European Journal of Cancer
, vol.41
, Issue.5
, pp. 702-707
-
-
Ravaud, A.1
Cerny, T.2
Terret, C.3
Wanders, J.4
Bui, B.N.5
Hess, D.6
Droz, J.-P.7
Fumoleau, P.8
Twelves, C.9
-
18
-
-
77953419543
-
A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion
-
ASCO
-
Pishvaian M, Marshall J, Hwang J, et al. A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. 2009 ASCO Annual Meeting. ASCO; 2009.
-
(2009)
2009 ASCO Annual Meeting
-
-
Pishvaian, M.1
Marshall, J.2
Hwang, J.3
-
19
-
-
77953411487
-
Use of vitamin PP compounds
-
inventors; PCT patent WO 99/53920. 21.04
-
Biedermann E, Hasmann M, Löser R, et al., inventors; Use of vitamin PP compounds. PCT patent WO 99/53920. 1999 21.04.
-
(1999)
-
-
Biedermann, E.1
Hasmann, M.2
Löser, R.3
-
20
-
-
40849119972
-
NAD+ and vitamin B3: From metabolism to therapies
-
Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008;324:883-93.
-
(2008)
J Pharmacol Exp Ther
, vol.324
, pp. 883-893
-
-
Sauve, A.A.1
-
21
-
-
34548329953
-
Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells
-
DOI 10.1074/jbc.M610357200
-
Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, Tsuchiya M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 2007;282:24574-82. (Pubitemid 47347525)
-
(2007)
Journal of Biological Chemistry
, vol.282
, Issue.34
, pp. 24574-24582
-
-
Hara, N.1
Yamada, K.2
Shibata, T.3
Osago, H.4
Hashimoto, T.5
Tsuchiya, M.6
-
22
-
-
62149150332
-
Niacin status, NAD distribution and ADP-ribose metabolism
-
Kirkland JB. Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des 2009;15:3-11.
-
(2009)
Curr Pharm des
, vol.15
, pp. 3-11
-
-
Kirkland, J.B.1
-
23
-
-
34447335060
-
Niacin in cardiovascular prevention: Mechanisms, efficacy, and safety
-
Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 2007;18:415-20.
-
(2007)
Curr Opin Lipidol
, vol.18
, pp. 415-420
-
-
Guyton, J.R.1
-
24
-
-
40349094705
-
Nicotinic acid: An old drug with a promising future
-
DOI 10.1038/sj.bjp.0707528, PII 0707528
-
Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008;153 Suppl 1:S68-75. (Pubitemid 351340990)
-
(2008)
British Journal of Pharmacology
, vol.153
, Issue.SUPPL. 1
-
-
Bodor, E.T.1
Offermanns, S.2
-
25
-
-
66449134807
-
Niacin status and treatment-related leukemogenesis
-
Kirkland JB. Niacin status and treatment-related leukemogenesis. Mol Cancer Ther 2009;8:725-32.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 725-732
-
-
Kirkland, J.B.1
-
26
-
-
0025064383
-
Nutritional deficiencies in patients receiving cancer chemotherapy
-
Dreizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad Med 1990;87:163-7, 70. (Pubitemid 20041617)
-
(1990)
Postgraduate Medicine
, vol.87
, Issue.1
, pp. 163-170
-
-
Dreizen, S.1
McCredie, K.B.2
Keating, M.J.3
Andersson, B.S.4
-
27
-
-
0023192879
-
Water-soluble vitamins in cancer patients on parenteral nutrition: A prospective study
-
Inculet RI, Norton JA, Nichoalds GE, Maher MM, White DE, Brennan MF. Water-soluble vitamins in cancer patients on parenteral nutrition: a prospective study. JPEN J Parenter Enteral Nutr 1987;11:243-9.
-
(1987)
JPEN J Parenter Enteral Nutr
, vol.11
, pp. 243-249
-
-
Inculet, R.I.1
Norton, J.A.2
Nichoalds, G.E.3
Maher, M.M.4
White, D.E.5
Brennan, M.F.6
-
28
-
-
0027173928
-
Pellagra secondary to 5-fluorouracil
-
Stevens HP, Ostlere LS, Begent RH, Dooley JS, Rustin MH. Pellagra secondary to 5-fluorouracil. Br J Dermatol 1993;128:578-80.
-
(1993)
Br J Dermatol
, vol.128
, pp. 578-580
-
-
Stevens, H.P.1
Ostlere, L.S.2
Begent, R.H.3
Dooley, J.S.4
Rustin, M.H.5
-
29
-
-
0022379935
-
Characterization of three new variant type cell lines derived from small cell carcinoma of the lung
-
de Leij L, Postmus PE, Buys CH, et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 1985;45:6024-33.
-
(1985)
Cancer Res
, vol.45
, pp. 6024-6033
-
-
De Leij, L.1
Postmus, P.E.2
Buys, C.H.3
-
30
-
-
34748893547
-
A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIα in vivo
-
DOI 10.1124/mol.107.036970
-
Grauslund M, Thougaard AV, Fuchtbauer A, et al. A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIα in vivo. Mol Pharmacol 2007;72:1003-14. (Pubitemid 47481423)
-
(2007)
Molecular Pharmacology
, vol.72
, Issue.4
, pp. 1003-1014
-
-
Grauslund, M.1
Thougaard, A.V.2
Fuchtbauer, A.3
Hofland, K.F.4
Hjorth, P.H.5
Jensen, P.B.6
Sehested, M.7
Fuchtbauer, E.-M.8
Jensen, L.H.9
-
31
-
-
0242317675
-
Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis
-
Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 2003;31:e73.
-
(2003)
Nucleic Acids Res
, vol.31
-
-
Peirson, S.N.1
Butler, J.N.2
Foster, R.G.3
-
32
-
-
34548627517
-
+ Levels Dictate Cell Survival
-
DOI 10.1016/j.cell.2007.07.035, PII S0092867407009737
-
Yang H, Yang T, Baur JA, et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007;130:1095-107. (Pubitemid 47410271)
-
(2007)
Cell
, vol.130
, Issue.6
, pp. 1095-1107
-
-
Yang, H.1
Yang, T.2
Baur, J.A.3
Perez, E.4
Matsui, T.5
Carmona, J.J.6
Lamming, D.7
Souza-Pinto, N.C.8
Bohr, V.A.9
Rosenzweig, A.10
De Cabo, R.11
Sauve, A.12
Sinclair, D.A.13
-
33
-
-
67650318141
-
Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777
-
Beauparlant P, Bedard D, Bernier C, et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 2009;20:346-54.
-
(2009)
Anticancer Drugs
, vol.20
, pp. 346-354
-
-
Beauparlant, P.1
Bedard, D.2
Bernier, C.3
-
34
-
-
33748707427
-
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents
-
Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nussler V, Hasmann M. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 2006;11:313-21. (Pubitemid 44390171)
-
(2006)
European Journal of Medical Research
, vol.11
, Issue.8
, pp. 313-321
-
-
Pogrebniak, A.1
Schemainda, I.2
Azzam, K.3
Pelka-Fleischer, R.4
Nussler, V.5
Hasmann, M.6
-
35
-
-
1842689677
-
Inhibition of human P450 enzymes by nicotinic acid and nicotinamide
-
DOI 10.1016/j.bbrc.2004.03.137, PII S0006291X0400645X
-
Gaudineau C, Auclair K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun 2004;317:950-6. (Pubitemid 38481464)
-
(2004)
Biochemical and Biophysical Research Communications
, vol.317
, Issue.3
, pp. 950-956
-
-
Gaudineau, C.E.1
Auclair, K.2
-
36
-
-
70350538957
-
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: Strategy for enhanced therapy in NAPRT1-deficient tumors
-
Watson M, Roulston A, Belec L, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in NAPRT1-deficient tumors. Mol Cell Biol 2009;29:5872-88.
-
(2009)
Mol Cell Biol
, vol.29
, pp. 5872-5888
-
-
Watson, M.1
Roulston, A.2
Belec, L.3
|